LENALIDOMIDE PHARMACOKINETICS IN COMBINATION WITH IDARUBION AND CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.

被引：0
|
作者：
Jiang, Y. [1 ]
Wang, J. [2 ]
Walker, A. [3 ]
Li, X. [4 ]
Drake, A. [2 ]
Schaaf, L. [2 ]
Byrd, J. [3 ]
Marcucci, G. [3 ]
Grever, M. [3 ]
Blum, W. [3 ]
Phelps, M. [1 ]
机构：
[1] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [31] COMBINATION OF CLOFARABINE AND CYTARABINE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
    Spassov, B.
    Balatzenko, G.
    Angelova, S.
    Toshkov, S.
    Guenova, M.
    Arnaudov, G.
    Mihaylov, G.
    HAEMATOLOGICA, 2015, 100 : 377 - 377
  • [32] Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia.
    Singhal, S
    Powles, R
    Treleaven, J
    Horton, C
    Hamblin, M
    Zomas, A
    Prendiville, J
    Saso, R
    Mackay, H
    Milan, S
    Mehta, J
    BLOOD, 1995, 86 (10) : 2039 - 2039
  • [33] Acute myeloid leukemia.: Reply
    Löwenberg, B
    Burnett, AK
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (05): : 358 - 359
  • [34] Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia
    Cortes, Jorge E.
    Jonas, Brian A.
    Graef, Thorsten
    Luan, Ying
    Stein, Anthony S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (08): : 509 - +
  • [35] More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
    Aldoss, Ibrahim
    Marcucci, Guido
    CHINESE CLINICAL ONCOLOGY, 2019, 8
  • [36] Cytogenetics in acute myeloid leukemia.
    Schoch C.
    Haferlach T.
    Current Oncology Reports, 2002, 4 (5) : 390 - 397
  • [37] A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia
    He, Fiona
    Sapkota, Smarika
    Parker, Sarah
    Defor, Todd
    Warlick, Erica
    Ustun, Celalettin
    Eckfeldt, Craig
    Rashidi, Armin
    Kurtzweil, Andy
    Weisdorf, Daniel
    Bejanyan, Nelli
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2352 - 2359
  • [38] Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
    Bhatnagar, Bhavana
    Walker, Alison R.
    Mims, Alice S.
    Vasu, Sumithira
    Klisovic, Rebecca B.
    Behbehani, Gregory
    Blachly, James Stewart
    Larkin, Karilyn T. M.
    Long, Meixiao
    Zhao, Qiuhong
    Ranganathan, Parvathi
    Byrd, John C.
    Blum, William G.
    Garzon, Ramiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] High incidence of deoxycytidine kinase inactivation in purified leukemic blasts of patients with cytarabine resistant acute myeloid leukemia.
    Veuger, MJT
    Honders, MW
    Willemze, R
    Landegent, JE
    Barge, RMY
    BLOOD, 1998, 92 (10) : 385A - 385A
  • [40] High dose cytarabine for acute biphenotypic leukemia.
    Jung, CW
    Lee, SI
    Lee, HR
    Park, SH
    Park, JO
    Kim, KH
    Kim, WS
    Im, YH
    Kang, WK
    Park, K
    Park, CH
    Lee, M
    BLOOD, 2001, 98 (11) : 213B - 213B
12345